HOME >> BIOLOGY >> NEWS
Insight into natural cholesterol control suggests novel cholesterol-lowering therapy

New work reported in the March issue of Cell Metabolism has provided insight into a key mechanism by which cells limit cholesterol synthesis. The finding suggests a novel approach to the development of cholesterol-lowering drugs that may boost the effect of statins, one of the most prescribed cholesterol inhibitors, according to researchers at the University of Texas Southwestern Medical Center.

Cells obtain cholesterol, an important component of cell membranes, by building it internally or by taking it up from the bloodstream. The cholesterol-building process involves more than 25 enzymes, including one called HMG CoA reductase, and many layers of regulatory control, said Russell DeBose-Boyd, senior author of the study.

Scientists have long known that cells respond to a high cholesterol diet by shutting down its internal synthesis, he explained. However, the molecular mechanisms by which cholesterol and other related compounds exert that self-control have only more recently begun to emerge.

The researchers now demonstrate that lanosterol--an intermediate compound in the synthetic pathway--mediates feedback control over the rate of cholesterol production by stimulating the degradation of cholesterol-building reductase. The availability of reductase, which functions early in the synthetic process, largely determines the rate of cellular cholesterol production, Debose-Boyd said.

When added to intact cells and cellular components in test tubes, lanosterol led other proteins to mark reductase for destruction by attaching a protein called ubiquitin in a process called ubiquitination. Ubiquitination is a common mechanism for stimulating protein degradation. Cholesterol itself had no such effect on reductase, even at much greater concentrations, they found.

"The current results demonstrate a direct role for lanosterol as a selective, physiologic regulator of reductase ubiquitination and degradation," said DeBose-Boyd. That effect wou
'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2979
Cell Press
15-Mar-2005


Page: 1 2

Related biology news :

1. Insights into osteosarcoma in cats and dogs may improve palliative care
2. Insight into evolution of adaptive immunity boosted by sea urchin genome sequencing
3. Insights into honey bee sex gene could bring sweet success in breeding
4. Insights into activity-dependent neuronal growth through RSRF-supported research
5. Symposium Environmental Change in Siberia -- Insights From Earth Observation and Modeling
6. Yale technology spins out varicose vein device company: Vascular Insights, LLC
7. Insight into our sight: A new view on the evolution of the eye lens
8. Insight into the processes of positive and negative learners
9. Insight into JAK/STAT
10. Insight into cell metabolism will help interpret PETs, MRIs
11. Insight into DNAs weakest links may yield clues to cancer biology

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/14/2018)... ... December 14, 2018 , ... uBiome, the leader in ... for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent and Trademark Office on ... is an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. ...
(Date:12/13/2018)... ... 2018 , ... Illumina, Kaiser Permanente, ResMed and Aetna were just a few ... and cooking events company has hosted an impressive guest list of Fortune 500 businesses, ... Each group who visits receives a completely customized experience, right down to the menu ...
(Date:12/10/2018)... , ... December 10, 2018 , ... ... strategic alliance to advance their shared goal of accelerating the development of the ... scale-up bioprocess systems to TRT’s core technology around human umbilical cord perivascular cells ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... ... January 08, 2019 , ... ... announced today that SAGICO will be represented at the 37th Annual J.P. ... Healthcare Conference is the largest and most informative healthcare investment symposium in ...
(Date:1/8/2019)... ... January 07, 2019 , ... ... members into Noninvasix. This represents the second investment AngelMD has made into Noninvasix ... morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively measure ...
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today ... drug candidate, code-named "KM-819." KM-819 is an orally active small molecule that ... South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was ...
(Date:1/4/2019)... ... January 01, 2019 , ... uBiome, the ... World Economic Forum Annual Meeting January 22-25, 2019 held in Davos-Klosters, Switzerland following ... World Economic Forum Annual Meeting brings together leaders of global society–the heads and ...
Breaking Biology Technology:
Cached News: